← All drugs Report issue

kw2449

Small moleculeexperimental

Clinical trial activity

2 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

2

Phase 2

0

Phase 3

0

Phase 4

0

Earliest trial started Jun 1, 2006 (NCT00346632)

Timeline

2000s

Jan 1, 2006
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Serine/threonine-protein kinase Aurora-BINHIBITOR
AURKB inhibitor
- Aurora kinase B (AURKB) ↗
Serine/threonine-protein kinase Aurora-AINHIBITOR
AURKA inhibitor
- Aurora kinase A (AURKA) ↗
Tyrosine-protein kinase ABLINHIBITOR
ABL1 inhibitor
- Tyrosine-protein kinase ABL1 (ABL1) ↗
Tyrosine-protein kinase receptor FLT3INHIBITOR
FLT3 inhibitor
- Receptor-type tyrosine-protein kinase FLT3 (FLT3) ↗

Chemistry & pharmacology

Loading structure…

SMILES

O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1

Mol. weight: 332.41 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL1908397 ↗

Also known as

kw2449
kw 2449
kw-2449
kw-2449
kw-2449
kw-2449

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00779480	Phase 1	Jan 1, 2009	Kyowa Hakko Kirin
NCT00346632	Phase 1	Jun 1, 2006	Kyowa Hakko Kirin, Kyowa Kirin

Showing 2 of 2 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Kyowa Hakko Kirin	For profit	2	2	1	2006
Kyowa Kirin	For profit	1	0	1	2006

2 organizations

Page 1 / 1